Treatment of Hepatocellular Carcinoma - PubMed (original) (raw)

Treatment of Hepatocellular Carcinoma

Josep M Llovet. Curr Treat Options Gastroenterol. 2004 Dec.

Abstract

Hepatocellular carcinoma is the fifth leading cause of cancer worldwide and its incidence is increasing. Surveillance programs allow doctors to identify patients at early stages of the disease, when the tumor may be curable by radical treatments such as resection, liver transplantation, or local ablation. In the West, these treatments can be applied to 30% to 40% of patients. Resection yields favorable results in patients with single tumors and a well-preserved liver function (5-year survival rate is 60%). Recurrence complicates two thirds of the cases, and there is no effective adjuvant treatment. Liver transplantation is the best treatment for patients with single tumors that are less than 5 cm in diameter and liver failure, or in those presenting with three nodules less than 3 cm, but organ shortage greatly limits its applicability. Long-term survival is expected to be around 50% to 70% at 5 years depending upon the drop-out rate of patients on the waiting list. Chemoembolization and local ablation are the neo-adjuvant treatments applied to patients on the waiting list to prevent tumor progression; no controlled study proving their efficacy has yet been published. In nonsurgical candidates, percutaneous treatments (ethanol injection or radiofrequency ablation) are the best therapeutic approach and improve survival in Child-Pugh A class patients with small tumors that achieve initial complete response (5-year survival rate is 40% to 50%). At more advanced stages, chemoembolization, a technique combining intra-arterial chemotherapy and selected ischemia, has shown to slightly improve survival in a meta-analysis of randomized trials. No survival advantages have been demonstrated with intra-arterial or systemic chemotherapy, hormonal compounds, or radiation. New agents, such as inhibitors of the tyrosine kinase receptors of growth factors and antiangiogenic agents, are currently being tested in phase II/III trials.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Gut. 2002 Jan;50(1):123-8 - PubMed
    1. Ann Intern Med. 1998 Oct 15;129(8):643-53 - PubMed
    1. N Engl J Med. 2001 May 24;344(21):1633-7 - PubMed
    1. Gastroenterology. 1995 Sep;109(3):917-22 - PubMed
    1. Radiology. 1995 Oct;197(1):101-8 - PubMed

LinkOut - more resources